Developmental Therapeutics Recent Publications

Nanotechnology approaches to drug delivery for the treatment of ischemic stroke.Peng B, Mohammed FS, Tang X, Liu J, Sheth KN, Zhou J. Bioact Mater. 2025 Jan; 2024 Sep 23. PMID: 39386225.
16S rRNA target sequencing of human tumors validates findings of Lachnoclostridium abundance in human melanomas that are heavily CD8+ T-cell infiltrated.Lu L, Johnson C, Khan S, Kluger H. Eur J Cancer. 2024 Dec; 2024 Oct 24. PMID: 39477777.
Utility of next generation sequencing to unequivocally establish clonality in synchronous vs metastatic endometrial and ovarian carcinomas.Greenman M, Bellone S, Hartwich T, Buza N, Santin AD. Gynecol Oncol Rep. 2024 Dec; 2024 Oct 2. PMID: 39435258.
Efficient standardization of clinical T(2)-weighted images: Phase-conjugacy e-CAMP with projected gradient descent.Zhang HZ, Elsaid NMH, Sun H, Tagare HD, Galiana G. Magn Reson Med. 2024 Dec; 2024 Jul 10. PMID: 38988054.
Branching in poly(amine-co-ester) polyplexes impacts mRNA transfection.Shin K, Suh HW, Suberi A, Whang CH, Ene M, Grundler J, Grun MK, Saltzman WM. Biomaterials. 2024 Dec; 2024 Jun 27. PMID: 38986360.
Vaping and tumor metastasis: current insights and progress.Xi Y, Yang L, Burtness B, Wang H. Cancer Metastasis Rev. 2024 Nov 25; 2024 Nov 25. PMID: 39581913.
Distinct epigenetic and transcriptional profiles of Epstein-Barr virus (EBV) positive and negative primary CNS lymphomas.Hai L, Friedel D, Hinz F, Hoffmann DC, Doubrovinskaia S, Rohdjess H, Weidenauer K, Denisova E, Scheffler GT, Kessler T, Kourtesakis A, Herold-Mende C, Henegariu O, Baehring JM, Dietrich J, Brors B, Wick W, Sahm F, Kaulen LD. Neuro Oncol. 2024 Nov 22; 2024 Nov 22. PMID: 39575767.
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma.Barata P, Tangen C, Plets M, Thompson IM Jr, Narayan V, George DJ, Heng DYC, Shuch B, Stein M, Gulati S, Tretiakova M, Tripathi A, Bjarnason GA, Humphrey P, Adeniran A, Vaishampayan U, Alva A, Zhang T, Cole S, Lara PN Jr, Lerner SP, Balzer-Haas N, Pal SK. J Clin Oncol. 2024 Nov 20; 2024 Sep 10. PMID: 39255440.
Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma.Schoenfeld DA, Djureinovic D, Su DG, Zhang L, Lu BY, Kamga L, Mann JE, Huck JD, Hurwitz M, Braun DA, Jilaveanu L, Ring AM, Kluger HM. JCI Insight. 2024 Nov 19; 2024 Nov 19. PMID: 39561007.
Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML.Alhajahjeh A, Patel KK, Shallis RM, Podoltsev NA, Kewan T, Stempel JM, Mendez L, Huntington SF, Stahl M, Goshua G, Bewersdorf JP, Zeidan AM. Leuk Lymphoma. 2024 Nov 19; 2024 Nov 19. PMID: 39560957.
MRI after focal therapy for prostate cancer: what radiologists must know?Jalilianhasanpour R, Arora S, Mansoori B, Raman S, Greenwood BM, Sprenkle P, Schade G, Camacho M, Hosseini N, Westphalen A. Abdom Radiol (NY). 2024 Nov 15; 2024 Nov 15. PMID: 39542951.
Synthesis of α-Quaternary Amides via Cp*Co(III)-Catalyzed Sequential C-H Bond Addition to 1,3-Dienes and Isocyanates.Yeo J, Tassone JP, Ellman JA. Org Lett. 2024 Nov 15; 2024 Oct 31. PMID: 39481088.
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer.Morgensztern D, Ready N, Johnson ML, Dowlati A, Choudhury N, Carbone DP, Schaefer E, Arnold SM, Puri S, Piotrowska Z, Hegde A, Chiang AC, Iams W, Tolcher A, Nosaki K, Kozuki T, Li T, Santana-Davila R, Akamatsu H, Murakami H, Yokouchi H, Wang S, Zha J, Li R, Robinson RR, Hingorani P, Jeng EE, Furqan M. Clin Cancer Res. 2024 Nov 15. PMID: 39287821.
Colibactin Exerts Androgen-dependent and -independent Effects on Prostate Cancer.Agrawal R, Al-Hiyari S, Hugh-White R, Hromas R, Patel Y, Williamson EA, Mootor MFE, Gonzalez A, Fu J, Haas R, Jordan M, Wickes BL, Mohammed G, Tian M, Doris MJ, Jobin C, Wernke KM, Pan Y, Yamaguchi TN, Herzon SB, Boutros PC, Liss MA. Eur Urol Oncol. 2024 Nov 14; 2024 Nov 14. PMID: 39547899.
Sorafenib or anthracycline-based chemotherapy for progressive desmoid tumors.Costa PA, Arora A, Fernandez Y, Yi I, Bakkila B, Tan H, Barreto Coelho P, Campoverde L, Hardy N, Bialick S, Espejo Freire A, D'Amato GZ, Chang YC, Mesenger JP, Subhawong T, Haims A, Hurwitz M, Olino K, Turaga K, Deshpande H, Trent J. Cancer. 2024 Nov 14; 2024 Nov 14. PMID: 39543805.
Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study.Sekeres MA, Santini V, Díez-Campelo M, Komrokji RS, Fenaux P, Savona MR, Madanat YF, Valcárcel-Ferreiras D, Oliva EN, Regnault A, Creel K, Sengupta N, Dougherty S, Shah S, Sun L, Wan Y, Navada S, Zeidan AM, Platzbecker U. Leuk Lymphoma. 2024 Nov 13; 2024 Nov 13. PMID: 39535901.
Pathologic prostate cancer grade concordance among high-resolution micro-ultrasound, systematic transrectal ultrasound and MRI fusion biopsy.Lokeshwar SD, Choksi AU, Smani S, Kong V, Sundaresan V, Sutherland R, Brito J, Renzulli JF, Sprenkle PC, Leapman MS. Urol Oncol. 2024 Nov 8; 2024 Nov 8. PMID: 39521675.
Risk prediction for clonal cytopenia: multicenter real-world evidence.Xie Z, Komrokji R, Al Ali N, Regelson A, Geyer S, Patel A, Saygin C, Zeidan AM, Bewersdorf JP, Mendez L, Kishtagari A, Zeidner JF, Coombs CC, Madanat YF, Chung S, Badar T, Foran J, Desai P, Tsai C, Griffiths EA, Al Malki MM, Amanam I, Lai C, Deeg HJ, Ades L, Arana Yi C, Osman AEG, Dinner S, Abaza Y, Taylor J, Chandhok N, Soong D, Brunner AM, Carraway HE, Singh A, Elena C, Ferrari J, Gallì A, Pozzi S, Padron E, Patnaik MM, Malcovati L, Savona MR, Al-Kali A. Blood. 2024 Nov 7. PMID: 38996210.
Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?El Chaer F, Perissinotti AJ, Loghavi S, Zeidan AM. Leukemia. 2024 Nov 5; 2024 Nov 5. PMID: 39496917.
Recommendations for monitoring adherence and fidelity in pragmatic trials based on experience in the Pain Management Collaboratory.Dziura J, Gilstad-Hayden K, Coffman CJ, Long CR, Yu Q, Buta E, Coggeshall S, Geda M, Peduzzi P, Kyriakides TC. Pain Med. 2024 Nov 1. PMID: 39514878.
Utility of the PICOTS framework to assess clinical trial disruptions: monitoring the impact of COVID-19 in the Pain Management Collaboratory.Peduzzi P, Brandt C, Dearth CL, Dziura J, Farrokhi S, George SZ, Kyriakides TC, Long CR, Mascha EJ, Patterson CG, Rhon DI, Kerns RD. Pain Med. 2024 Nov 1. PMID: 39514876.
Achieving two-part harmony: standardizing pain-related phenotypes and outcomes.Edwards R, Geda M, Burgess DJ, Davis AF, DeBar L, Pal N, Peduzzi P, Taylor SL, Wallace R, Luther SL. Pain Med. 2024 Nov 1. PMID: 39514875.
Adapting to change: experiences and recommendations from the Pain Management Collaboratory on modifying statistical analysis plans.Yu Q, George SZ, Kyriakides TC, Rhon DI, Morasco BJ, Dziura J, Fritz JM, Geda M, Peduzzi P, Long CR. Pain Med. 2024 Nov 1. PMID: 39514871.
A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS.Norman M, Yamartino K, Gerstein R, Shallis R, Mendez L, Podoltsev N, Stahl M, Eighmy W, Zeidan AM. Expert Rev Hematol. 2024 Nov; 2024 Nov 7. PMID: 39474840.
The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development.Colombo R, Tarantino P, Rich JR, LoRusso PM, de Vries EGE. Cancer Discov. 2024 Nov 1. PMID: 39439290.
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes.Komrokji RS, Lanino L, Ball S, Bewersdorf JP, Marchetti M, Maggioni G, Travaglino E, Al Ali NH, Fenaux P, Platzbecker U, Santini V, Diez-Campelo M, Singh A, Jain AG, Aguirre LE, Tinsley-Vance SM, Schwabkey ZI, Chan O, Xie Z, Brunner AM, Kuykendall AT, Bennett JM, Buckstein R, Bejar R, Carraway HE, DeZern AE, Griffiths EA, Halene S, Hasserjian RP, Lancet J, List AF, Loghavi S, Odenike O, Padron E, Patnaik MM, Roboz GJ, Stahl M, Sekeres MA, Steensma DP, Savona MR, Taylor J, Xu ML, Sweet K, Sallman DA, Nimer SD, Hourigan CS, Wei AH, Sauta E, D'Amico S, Asti G, Castellani G, Delleani M, Campagna A, Borate UM, Sanz G, Efficace F, Gore SD, Kim TK, Daver N, Garcia-Manero G, Rozman M, Orfao A, Wang SA, Foucar MK, Germing U, Haferlach T, Scheinberg P, Miyazaki Y, Iastrebner M, Kulasekararaj A, Cluzeau T, Kordasti S, van de Loosdrecht AA, Ades L, Zeidan AM, Della Porta MG. Lancet Haematol. 2024 Nov; 2024 Oct 9. PMID: 39393368.
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Lieghl N, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Jänne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. Nature. 2024 Nov; 2024 Oct 9. PMID: 39385035.
Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions.Bidikian A, Bewersdorf JP, Shallis RM, Getz TM, Stempel JM, Kewan T, Stahl M, Zeidan AM. Expert Rev Anticancer Ther. 2024 Nov; 2024 Oct 17. PMID: 39367718.
IL-1β Induces Human Endothelial Surface Expression of IL-15 by Relieving let-7c-3p Suppression of Protein Translation.Mullan CW, Summer L, Lopez-Giraldez F, Tobiasova Z, Manes TD, Yasothan S, Song G, Jane-Wit D, Saltzman WM, Pober JS. J Immunol. 2024 Nov 1. PMID: 39302113.
Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer.Sundaresan VM, Wang R, Long JB, Sprenkle PC, Seibert TM, Loeb S, Cooperberg MR, Catalona WJ, Ma X, Gross CP, Leapman MS. Urol Pract. 2024 Nov; 2024 Jul 16. PMID: 39196719.
Chitinase 3-like-1 (CHI3L1) in the pathogenesis of epidermal growth factor receptor mutant non-small cell lung cancer.Kamle S, Ma B, Schor G, Bailey M, Pham B, Cho I, Khan H, Azzoli C, Hofstetter M, Sadanaga T, Herbst R, Politi K, Lee CG, Elias JA. Transl Oncol. 2024 Nov; 2024 Aug 22. PMID: 39178575.
Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape.Weller M, Remon J, Rieken S, Vollmuth P, Ahn MJ, Minniti G, Le Rhun E, Westphal M, Brastianos PK, Soo RA, Kirkpatrick JP, Goldberg SB, Öhrling K, Hegi-Johnson F, Hendriks LEL. Cancer Treat Rev. 2024 Nov; 2024 Aug 2. PMID: 39151281.
Factors influencing timely diagnosis in neurolymphomatosis.Doubrovinskaia S, Egert A, Karschnia P, Scheffler GT, Traub BL, Galluzzo D, Huttner A, Fulbright RK, Baehring JM, Kaulen LD. J Neurooncol. 2024 Nov; 2024 Aug 8. PMID: 39115616.
Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study.Philip PA, Sahai V, Bahary N, Mahipal A, Kasi A, Rocha Lima CMS, Alistar AT, Oberstein PE, Golan T, Metges JP, Lacy J, Fountzilas C, Lopez CD, Ducreux M, Hammel P, Salem M, Bajor D, Benson AB, Luther S, Pardee T, Van Cutsem E. J Clin Oncol. 2024 Nov; 2024 Aug 1. PMID: 39088774.
Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era.Lee DY, McNamara M, Yang A, Yaskolko M, Kluger H, Tran T, Olino K, Clune J, Sznol M, Ishizuka JJ. Pigment Cell Melanoma Res. 2024 Nov; 2024 Jul 28. PMID: 39073002.
Association of Crowd-Sourced Assessment of Technical Skills and Outcomes of Robotic-assisted Radical Prostatectomy.Rabil MJ, Jalfon M, Heckscher D, Song Z, Li F, Martin T, Sprenkle PC, Hesse D, Kim IY, Leapman MS, Cavallo JA. Urology. 2024 Nov; 2024 Jul 15. PMID: 39019332.
Risk of Pancreatitis After Endoscopic Ultrasound-Guided Fine-Needle Aspiration of Pancreatic Cystic Lesions: A Systematic Review and Meta-Analysis.Magahis PT, Chhoda A, Berzin TM, Farrell JJ, Wright DN, Rizvi A, Hanscom M, Carr-Locke DL, Sampath K, Sharaiha RZ, Mahadev S. Am J Gastroenterol. 2024 Nov 1; 2024 Jul 5. PMID: 38976379.
Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome.Alhajahjeh A, Bewersdorf JP, Bystrom RP, Zeidan AM, Shimony S, Stahl M. Leuk Lymphoma. 2024 Nov; 2024 Jul 4. PMID: 38962996.
Procoagulant phenotype of virus-infected pericytes is associated with portal thrombosis and intrapulmonary vascular dilations in fatal COVID-19.Cadamuro M, Lasagni A, Radu CM, Calistri A, Pilan M, Valle C, Bonaffini PA, Vitiello A, Toffanin S, Venturin C, Friòn-Herrera Y, Sironi S, Alessio MG, Previtali G, Seghezzi M, Gianatti A, Strazzabosco M, Strain AJ, Campello E, Spiezia L, Palù G, Frigo AC, Tosoni A, Nebuloni M, Parolin C, Sonzogni A, Simioni P, Fabris L. J Hepatol. 2024 Nov; 2024 Jun 20. PMID: 38908437.
Prognostic impact of 'multi-hit' versus 'single-hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases.Badar T, Nanaa A, Atallah E, Shallis RM, Craver EC, Li Z, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, Duvall A, Burkart M, Bradshaw D, Abaza Y, Stahl M, Palmisiano N, Murthy GSG, Zeidan AM, Kota V, Patnaik MM, Litzow MR. Haematologica. 2024 Nov 1; 2024 Nov 1. PMID: 38813716.
Mapping intratumoral myeloid-T cell interactomes at single-cell resolution reveals targets for overcoming checkpoint inhibitor resistance.Bridges K, Pizzurro GA, Baysoy A, Baskaran JP, Xu Z, Mathew V, Tripple V, LaPorte M, Park K, Damsky W, Kluger H, Fan R, Kaech SM, Bosenberg MW, Miller-Jensen K. bioRxiv. 2024 Oct 31; 2024 Oct 31. PMID: 39554094.
Microbial transformation of dietary xenobiotics shapes gut microbiome composition.Culp EJ, Nelson NT, Verdegaal AA, Goodman AL. Cell. 2024 Oct 31; 2024 Sep 24. PMID: 39321800.
First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.Shimizu T, Powderly J, Abdul Razak A, LoRusso P, Miller KD, Kao S, Kongpachith S, Tribouley C, Graham M, Stoll B, Patel M, Sahtout M, Blaney M, Leibman R, Golan T, Tolcher A. Front Oncol. 2024; 2024 Oct 29. PMID: 39534099.
Next steps for targeted protein degradation.Krone MW, Crews CM. Cell Chem Biol. 2024 Oct 29; 2024 Oct 29. PMID: 39500325.
Analyzing determinants of premature trial discontinuation in leukemia clinical trials.Rotter LK, Alhajahjeh A, Stempel JM, Grimshaw AA, Bewersdorf JP, Blaha O, Kewan T, Podoltsev NA, Shallis RM, Mendez L, Stahl M, Zeidan AM. Leuk Lymphoma. 2024 Oct 23; 2024 Oct 23. PMID: 39440622.
Inter-reader reliability and diagnostic accuracy of PI-RADS scoring between academic and community care networks: How wide is the gap?Smani S, Jalfon M, Sundaresan V, Lokeshwar SD, Nguyen J, Halstuch D, Khajir G, Cavallo JA, Sprenkle PC, Leapman MS, Kim IY. Urol Oncol. 2024 Oct 21; 2024 Oct 21. PMID: 39438211.
Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC).Pike LRG, Miao E, Boe LA, Patil T, Imber BS, Myall NJ, Pollom EL, Hui C, Qu V, Langston J, Chiang V, Grant M, Goldberg SB, Palmer JD, Prasad RN, Wang TJC, Lee A, Shu CA, Chen LN, Thomas NJ, Braunstein SE, Kavanagh BD, Camidge DR, Rusthoven CG. J Clin Oncol. 2024 Oct 20; 2024 Jul 24. PMID: 39047224.
Impacts of Medications on Microbiome-mediated Protection against Enteric Pathogens.Kumar A, Sun R, Habib B, Bencivenga-Barry NA, Ivanov II, Tamblyn R, Goodman AL. Res Sq. 2024 Oct 18; 2024 Oct 18. PMID: 39483881.
Incidence of bacterial blood stream infections in patients with acute GVHD.Wallis W, Gulbis AM, Wang T, Lee CJ, Sharma A, Williams KM, Nishihori T, Prestidge T, Gowda L, Byrne M, Krem MM, MacMillan ML, Kitko CL, Pidala J, Spellman SR, Lee SJ, Alousi AM. Bone Marrow Transplant. 2024 Oct 18; 2024 Oct 18. PMID: 39420192.
Mucosal sugars delineate pyrazine vs pyrazinone autoinducer signaling in Klebsiella oxytoca.Hamchand R, Wang K, Song D, Palm NW, Crawford JM. Nat Commun. 2024 Oct 16; 2024 Oct 16. PMID: 39406708.
High-quality lipid suppression and B0 shimming for human brain (1)H MRSI.Kumaragamage C, McIntyre S, Nixon TW, De Feyter HM, de Graaf RA. Neuroimage. 2024 Oct 15; 2024 Sep 12. PMID: 39276817.
A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma.Schuetze SM, Ballman KV, Heise R, Ganjoo KN, Davis EJ, George S, Burgess MA, Choy E, Shepard DR, Tinoco G, Hirbe A, Kelly CM, Attia S, Deshpande HA, Schwartz GK, Siontis BL, Riedel RF, von Mehren M, Kozlowski E, Chen HX, Astbury C, Rubin BP. Clin Cancer Res. 2024 Oct 15. PMID: 38446990.
Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.Yasin F, Sokol E, Vasan N, Pavlick DC, Huang RSP, Pelletier M, Levy MA, Pusztai L, Lacy J, Zhang JY, Ross JS, Cecchini M. Oncologist. 2024 Oct 14; 2024 Oct 14. PMID: 39401325.
Enantioselective S-Alkylation of Sulfenamides by Phase-Transfer Catalysis.Champlin AT, Kwon NY, Ellman JA. Angew Chem Int Ed Engl. 2024 Oct 14; 2024 Sep 12. PMID: 39058627.
Catabolism of extracellular glutathione supplies amino acids to support tumor growth.Hecht F, Zocchi M, Tuttle ET, Ward NP, Smith B, Kang YP, Cazarin J, Soares ZG, Ozgurses ME, Zhao H, Sheehan C, Alimohammadi F, Munger LD, Trivedi D, Asantewaa G, Blick-Nitko SK, Zoeller JJ, Chen Y, Vasiliou V, Turner BM, Muir A, Coloff JL, Munger J, DeNicola GM, Harris IS. bioRxiv. 2024 Oct 13; 2024 Oct 13. PMID: 39416022.
Synthesis of Monodehydro-Diketopiperazines Enabled by Cp*Rh(III)-Catalyzed Amine-Directed N-H Functionalization.Molas JC, Poag EM, Ellman JA. Org Lett. 2024 Oct 11; 2024 Sep 27. PMID: 39332014.
Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer.Santin AD, Corr BR, Spira A, Willmott L, Butrynski J, Tse KY, Patel J, Mekan S, Wu T, Lin KW, Kuo P, Dumbrava EE. J Clin Oncol. 2024 Oct 10; 2024 Jul 31. PMID: 39083724.
SIMVI reveals intrinsic and spatial-induced states in spatial omics data.Dong M, Su D, Kluger H, Fan R, Kluger Y. bioRxiv. 2024 Oct 10; 2024 Oct 10. PMID: 37693629.
Bacterial small molecule metabolites implicated in gastrointestinal cancer development.Turocy T, Crawford JM. Nat Rev Microbiol. 2024 Oct 7; 2024 Oct 7. PMID: 39375475.
Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.Botta GP, Abdelrahim M, Drengler RL, Aushev VN, Esmail A, Laliotis G, Brewer CM, George GV, Abbate SM, Chandana SR, Tejani MA, Malla M, Bansal D, Rivero-Hinojosa S, Spickard E, McCormick N, Cecchini M, Lacy J, Fei N, Kasi PM, Kasi A, Dayyani F, Hanna DL, Sharma S, Malhotra M, Aleshin A, Liu MC, Jurdi A. Oncologist. 2024 Oct 3. PMID: 39022993.
Topography of mutational signatures in non-small cell lung cancer: emerging concepts, clinical applications, and limitations.Jayakrishnan R, Kwiatkowski DJ, Rose MG, Nassar AH. Oncologist. 2024 Oct 3. PMID: 38907669.
Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients.Wang JZ, Landry AP, Raleigh DR, Sahm F, Walsh KM, Goldbrunner R, Yefet LS, Tonn JC, Gui C, Ostrom QT, Barnholtz-Sloan J, Perry A, Ellenbogen Y, Hanemann CO, Jungwirth G, Jenkinson MD, Tabatabai G, Mathiesen TI, McDermott MW, Tatagiba M, la Fougère C, Maas SLN, Galldiks N, Albert NL, Brastianos PK, Ehret F, Minniti G, Lamszus K, Ricklefs FL, Schittenhelm J, Drummond KJ, Dunn IF, Pathmanaban ON, Cohen-Gadol AA, Sulman EP, Tabouret E, Le Rhun E, Mawrin C, Moliterno J, Weller M, Bi WL, Gao A, Yip S, Niyazi M, Aldape K, Wen PY, Short S, Preusser M, Nassiri F, Zadeh G. Neuro Oncol. 2024 Oct 3. PMID: 38695575.
NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion.Noronha KJ, Lucas KN, Paradkar S, Edmonds J, Friedman S, Murray MA, Liu S, Sajed DP, Sachs C, Spurrier J, Raponi M, Liang J, Zeng H, Sundaram RK, Shuch B, Vasquez JC, Bindra RS. Mol Cancer Res. 2024 Oct 2. PMID: 38949523.
Long-Term Outcomes of Prostate-Specific Membrane Antigen-PET Imaging of Recurrent Prostate Cancer.Kunst N, Long JB, Westvold S, Sprenkle PC, Kim IY, Saperstein L, Rabil M, Ghaffar U, Karnes RJ, Ma X, Gross CP, Wang SY, Leapman MS. JAMA Netw Open. 2024 Oct 1; 2024 Oct 1. PMID: 39441595.
A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B-cell or T-cell acute lymphoblastic leukemia: Results from the ECOG-ACRIN EA9152 protocol.Palmisiano ND, Lee JW, Claxton DF, Paietta EM, Alkhateeb H, Park J, Podoltsev NA, Atallah EL, Schaar DG, Dinner SN, Webster JA, Luger SM, Litzow MR. EJHaem. 2024 Oct; 2024 Aug 8. PMID: 39415930.
Unmet needs in cervical cancer - can biological therapies plug the gap?Greenman M, Chang YE, McNamara B, Mutlu L, Santin AD. Expert Opin Biol Ther. 2024 Oct; 2024 Sep 25. PMID: 39311611.
CYP2E1 in 1,4-dioxane metabolism and liver toxicity: insights from CYP2E1 knockout mice study.Wang Y, Charkoftaki G, Orlicky DJ, Davidson E, Aalizadeh R, Sun N, Ginsberg G, Thompson DC, Vasiliou V, Chen Y. Arch Toxicol. 2024 Oct; 2024 Aug 27. PMID: 39192018.
Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis.Muradashvili T, Yu M, Browning SL, Bar N, Gorshein E, Parker TL, Neparidze N. Leukemia. 2024 Oct; 2024 Aug 20. PMID: 39164408.
Addressing platelet insecurity - A national call to action.Gehrie EA, Young PP, Basavaraju SV, Bracey AW, Cap AP, Culler L, Dunbar NM, Homer M, Isufi I, Macedo R, Petraszko T, Ramsey G, Tormey CA, Kaufman RM, Snyder EL. Transfusion. 2024 Oct; 2024 Aug 12. PMID: 39133194.
Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma.Tripathi A, Tangen CM, Plets M, Li X, Tretiakova M, Humphrey PA, Adeniran A, Barata PC, Gulati S, Bergerot CD, Pruthi DK, Thompson IM, Lara PN Jr, Lerner SP, Pal SK, Shuch BM. BJU Int. 2024 Oct; 2024 Jul 16. PMID: 39014969.
Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma.McNamara B, Greenman M, Bellone S, Santin LA, Demirkiran C, Mutlu L, Hartwich TMP, Yang-Hartwich Y, Ratner E, Schwartz PE, Santin AD. Gynecol Oncol. 2024 Oct; 2024 Jul 8. PMID: 38981151.
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2.Mutlu L, McNamara B, Bellone S, Manavella DD, Demirkiran C, Greenman M, Verzosa MSZ, Buza N, Hui P, Hartwich TMP, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Schwartz PE, Santin AD. Clin Exp Metastasis. 2024 Oct; 2024 Jun 22. PMID: 38909139.
Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy.Diaz GM, Webb LT, Rabil MJ, Lokeshwar SD, Choksi AU, Leapman MS, Sprenkle PC. Curr Urol Rep. 2024 Oct; 2024 Jun 19. PMID: 38896314.
Automated graded prognostic assessment for patients with hepatocellular carcinoma using machine learning.Gross M, Haider SP, Ze'evi T, Huber S, Arora S, Kucukkaya AS, Iseke S, Gebauer B, Fleckenstein F, Dewey M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey JA. Eur Radiol. 2024 Oct; 2024 Mar 27. PMID: 38536464.
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML.Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Bystrom RP, Lindsley RC, Chen EC, Ramos Perez J, Stein A, Pullarkat V, Aldoss I, DeAngelo DJ, Neuberg DS, Stone RM, Garciaz S, Ball B, Stahl M. Blood Adv. 2024 Sep 24. PMID: 38941537.
Treatment Patterns and Clinical Outcomes in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer After Progression on Osimertinib.Robinson ND, Canavan ME, Zhan PL, Udelsman BV, Pathak R, Boffa DJ, Goldberg SB. Clin Lung Cancer. 2024 Sep 23; 2024 Sep 23. PMID: 39462746.
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]).Aakash F, Gisriel SD, Zeidan AM, Bennett JM, Bejar R, Bewersdorf JP, Borate UM, Boultwood J, Brunner AM, Buckstein R, Carraway HE, Churpek JE, Daver NG, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Garcia-Manero G, Gore SD, Greenberg PL, Griffiths EA, Halene S, Hourigan CS, Kim TK, Kim N, Komrokji RS, Kutchroo VK, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Platzbecker U, Della Porta MG, Roboz GJ, Sallman DA, Santini V, Sanz G, Savona MR, Sekeres MA, Stahl M, Starczynowski DT, Steensma DP, Taylor J, Abdel-Wahab O, Wei AH, Xie Z, Xu ML, Hasserjian RP, Loghavi S. Mod Pathol. 2024 Sep 23; 2024 Sep 23. PMID: 39322118.
Disulfide Tethering to Map Small Molecule Binding Sites Transcriptome-wide.Moon MH, Vock IW, Streit AD, Connor LJ, Senkina J, Ellman JA, Simon MD. ACS Chem Biol. 2024 Sep 20; 2024 Aug 28. PMID: 39192734.
Prodrug nanotherapy demonstrates in vivo anticryptosporidial efficacy in a mouse model of chronic Cryptosporidium infection.Ranjan AP, Czyzyk DJ, Martinez-Traverso G, Sadiqova A, Valhondo M, Schaefer DA, Spasov KA, Jorgensen WL, Vishwanatha JK, Riggs MW, Castellanos-Gonzalez A, Anderson KS. RSC Pharm. 2024 Sep 19; 2024 Sep 19. PMID: 39372445.
Development of Ligands and Degraders Targeting MAGE-A3.Li K, Krone MW, Butrin A, Bond MJ, Linhares BM, Crews CM. J Am Chem Soc. 2024 Sep 11; 2024 Aug 27. PMID: 39190582.
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC.Nassar AH, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung JM, Lin JJ, Liu Y, Lin SH, Parikh K, Sridhar A, Shakya P, Dilling TJ, Kaldas D, Gray JE, Lobachov A, Bar J, Luders H, Grohe C, Gupta S, Leal T, Fitzgerald B, Crowley F, Fujiwara Y, Marron TU, Wilgucki M, Reuss J, Chen L, Sankar K, Aredo JV, Neal JW, Wakelee HA, Thummalapalli R, Yu H, Whitaker R, Velazquez A, Ragavan M, Cortellini A, Kwiatkowski DJ, Naqash AR, Goldberg SB, Kim SY. J Thorac Oncol. 2024 Sep 10; 2024 Sep 10. PMID: 39260522.
Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma.Straining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Clin Lymphoma Myeloma Leuk. 2024 Sep 8; 2024 Sep 8. PMID: 39368885.
Portal Fibrosis and the Ductular Reaction: Pathophysiological Role in the Progression of Liver Disease and Translational Opportunities.Gupta V, Sehrawat TS, Pinzani M, Strazzabosco M. Gastroenterology. 2024 Sep 7; 2024 Sep 7. PMID: 39251168.
Dynamic and structural insights into allosteric regulation on MKP5 a dual-specificity phosphatase.Skeens E, Maschietto F, Manjula R, Shillingford S, Lolis EJ, Batista VS, Bennett AM, Lisi GP. bioRxiv. 2024 Sep 5; 2024 Sep 5. PMID: 39282375.
Pancreatic Cysts.Gonda TA, Cahen DL, Farrell JJ. N Engl J Med. 2024 Sep 5. PMID: 39231345.
Aplastic anemia in association with multiple myeloma: clinical and pathophysiological insights.Muradashvili T, Liu Y, VanOudenhove J, Gu SX, Krause DS, Montanari F, Carlino MJ, Mancuso R, Stempel JM, Halene S, Zeidan AM, Podoltsev NA, Neparidze N. Leuk Lymphoma. 2024 Sep 3; 2024 Sep 3. PMID: 39225418.
Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors.Choi Y, Dharia NV, Jun T, Chang J, Royer-Joo S, Yau KK, Assaf ZJ, Aimi J, Sivakumar S, Montesion M, Sacher A, LoRusso P, Desai J, Schutzman JL, Shi Z. Clin Cancer Res. 2024 Sep 3. PMID: 38995268.
Management of recurrent and persistent malignant ovarian germ cell tumors: a narrative review.Nasioudis D, Pashankar FD. Int J Gynecol Cancer. 2024 Sep 2; 2024 Sep 2. PMID: 38991656.
Pilot PET study of vaginally administered bioadhesive nanoparticles in cynomolgus monkeys: Kinetics and safety evaluation.Grun MK, Honhar P, Wang Y, Rossano S, Khang M, Suh HW, Fowles K, Kliman HJ, Cavaliere A, Carson RE, Marquez-Nostra B, Saltzman WM. Bioeng Transl Med. 2024 Sep; 2024 May 9. PMID: 39553429.
Preclinical evaluation of avutometinib and defactinib in high-grade endometrioid endometrial cancer.Hartwich TMP, Mansolf M, Demirkiran C, Greenman M, Bellone S, McNamara B, Nandi SP, Alexandrov LB, Yang-Hartwich Y, Coma S, Pachter J, Santin AD. Cancer Med. 2024 Sep. PMID: 39240189.
Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson MB, Sun H, Roarty E, Goldberg SB, Brahmer JR, Altan M, Lu C, Papadimitrakopoulou V, Politi K, Doebele RC, Wong KK, Heymach JV. Nat Med. 2024 Sep. PMID: 39164519.
Akt is a mediator of artery specification during zebrafish development.Zhou W, Ghersi JJ, Ristori E, Semanchik N, Prendergast A, Zhang R, Carneiro P, Baldissera G, Sessa WC, Nicoli S. Development. 2024 Sep 1; 2024 Sep 2. PMID: 39101673.
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.Della Porta MG, Garcia-Manero G, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcárcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Pilot R, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Prebet T, Lai Y, Degulys A, Paolini S, Cluzeau T, Fenaux P, Platzbecker U. Lancet Haematol. 2024 Sep; 2024 Jul 19. PMID: 39038479.
Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.Dzienis M, Cundom J, Fuentes CS, Spreafico A, Nordlinger M, Pastor AV, Alesi E, Neki A, Fung AS, Figueiredo Lima IP, Oppelt P, da Cunha Junior GF, Burtness B, Franke FA, Tseng JE, Joshi A, McCarthy J, Swaby R, Sidi Y, Gumuscu B, Naicker N, de Castro G Jr. J Clin Oncol. 2024 Sep 1; 2024 Jul 22. PMID: 39038265.
Enterococcus faecalis-derived adenine enhances enterohaemorrhagic Escherichia coli Type 3 Secretion System-dependent virulence.Martins FH, Rosay T, Rajan A, Carter HE, Turocy T, Mejia A, Crawford JM, Maresso AW, Sperandio V. Nat Microbiol. 2024 Sep; 2024 Jul 4. PMID: 38965331.
Quantitative Measurement of HER2 Expression in Non-Small Cell Lung Cancer With a High-Sensitivity Assay.Liu M, Vathiotis I, Robbins CJ, Chan NNN, Moutafi M, Burela S, Xirou V, Schalper KA, Herbst RS, Syrigos K, Rimm DL. Mod Pathol. 2024 Sep; 2024 Jul 2. PMID: 38964502.
Patterns of brain metastases response to immunotherapy with pembrolizumab.Mahajan A, Goldberg SL, Weiss SA, Tran T, Singh K, Joshi K, Aboian MS, Kluger HM, Chiang VL. J Neurooncol. 2024 Sep; 2024 Jul 4. PMID: 38963658.
Outcomes Following Implementation of an Electronic Model for Perioperative Hematologic Consultation.Su DG, Rehman S, Wang K, Deng Y, Rose MG, Dosani T, Kunstman JW. J Surg Res. 2024 Sep; 2024 Jun 20. PMID: 38905768.
ZFYVE21 promotes endothelial nitric oxide signaling and vascular barrier function in the kidney during aging.Jiang Q, Song G, He L, Li X, Jiang B, Wang Q, Wang S, Kim C, Barkestani MN, Lopez R, Fan M, Wanniarachchi K, Quaranta M, Tian X, Mani A, Gonzalez A, Goodwin JE, Sessa WC, Ishibe S, Jane-Wit D. Kidney Int. 2024 Sep; 2024 May 24. PMID: 38797325.
Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208).Hochster HS, Catalano P, Weitz M, Mitchell EP, Cohen D, O'Dwyer PJ, Faller BA, Kortmansky JS, O'Hara MH, Kricher SM, Lacy J, Lenz HJ, Verma U, Benson AB. J Natl Cancer Inst. 2024 Sep 1. PMID: 38775718.